HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Semaglutide cut inflammation 38% in SELECT; biggest drops tracked with fewer events

Louis Nervegna · Aug 21, 2026 · ♥ 20 reactions · 4 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Inflammation & CRPHeart attack, stroke & procedures
AI summary & key facts

A new analysis of the SELECT trial asks why semaglutide reduced cardiovascular events. Inflammation markers fell 38% versus placebo, early and even in people who lost little weight, and those with the biggest drops had the fewest events. Modelling suggests part of the drug's benefit runs through lower inflammation, though this shows a link rather than proof of cause.

In the huge SELECT randomized trial, the GLP1 agonist Semaglutide cut inflammation markers by 38% versus placebo. Much of the drop occurred even before weight loss was seen. The patients who saw the largest drops in inflammation on Semaglutide had the fewest heart attacks and other cardiovascular events in the trial.

#glp1HD #glp1inflammationHD #inflammationHD #semaglutideHD #selectHD

Research cited

Inflammation is a major driver of heart disease. Weight loss medications significantly reduce it.

In SELECT, 17,604 people with existing heart disease and overweight or obesity were given semaglutide or a placebo. The trial already showed 20% fewer heart attacks, strokes, and cardiovascular deaths. This new analysis asks why.

People with the most inflammation had 2 to 4 times the risk of a heart attack, stroke, or death compared with those with the least. Semaglutide cut inflammation markers by 38% versus placebo and the drop came early, showing up before most of the weight loss did. It happened even in people who lost little to no weight, and separately from any change in cholesterol.

Patients whose inflammation fell the most also had fewer cardiovascular events. Modelling suggests a meaningful share of the drug’s benefit traces back to this drop in inflammation though this kind of analysis can show a link, not prove that lowering inflammation itself is what caused it.

Save this and share it with someone managing heart disease.

📄 Plutzky J, Bogdański P, Colhoun HM, et al. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT. Circulation. 2026;154:e074482.

May be a graphic of text that says 'INFLAMMATION & HEART DISEASE 01/10 01/10 Inflammation is a major driver ofheart disease. Weight Loss Medications Significantly Reduce It. Plutzky Puty/.eralCrubtn2z6154 J etal et tal Circulation. 2026:154:e074482 @drpaddybarrett'May be a graphic of text that says 'THE STUDY 02 02/10 10 Who this trial looked at. 17,604 people with existing heart disease Tested semaglutide vs. placebo. Overweight or obese. No diabetes. Followed for over 3 years. PuztyuJeralCrcubto.2026:5407 Puety/cel.rdbeto.-oz614 T Plutzky et al. al. Circulation. 2026 2026:154:e074482 @drpaddybarrett'May be a graphic of heart and text that says 'THE HEADLINE THEHEADLINERESULT RESULT 03 03/10 10 It already cuts heart attacks. 20% fewer heart attacks, strokes, and deaths Compared with placebo. This paper asks why. Plutzky e PuztyueralCrceto.2026154074 받! al. Circulation, 2026;154e074482 @drpaddybarrett'May be a graphic of text that says 'INFLAMMATION PREDICTS RISK 04 04/10 10 More inflammation, more risk. Heart attack or stroke 2.2x 2x 2. Cardiovascular death 3.9x 3.9x Death, any cause 3.4x Risk in patients with the most inflammation, versus the least. Plutzky e t al. al Circulation. 2026,154e074482 @drpaddybarrett'May be a graphic of text that says 'WHAT SEMAGLUTIDE LUTIDE DID 05 10 05/10 Ο It calmed the inflammation. 38% drop in inflammation markers Versus placebo, over two years. Plutzky PutdyLeta.Cirauaton.026,54-074 et al. Circulation 2026,154e074482 e @drpaddybarrett'
← newer: Dietary choline may protect mitochondria and slow brain-cellolder: Blood tests and AI scan analysis are improving early detecti →